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ABSTRACT 
Cardiovascular diseases (CVDs) are among the leading causes of mortality in the US and 
worldwide. Cholesterol at high levels in circulation has been established as a major risk factor 
for CVDs in humans. Statins, the cholesterol-lowering drugs, have been widely used for 
lowering and controlling the endogenous levels of cholesterol to prevent or treat CVDs. Statins 
lower cholesterol by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA 
reductase), the rate-limiting enzyme in the biosynthetic pathway of endogenous cholesterol. On 
the other hand, statins are known to cause skeletal muscle damage (myotoxicity and myalgia) in 
humans while administered to lower the circulating cholesterol levels for the treatment of CVDs.  
However, the mechanisms and treatment of statin-induced myotoxicity and myalgia are not 
thoroughly established. Phospholipase D (PLD), a membrane phospholipid-hydrolyzing enzyme 
is ubiquitous and involved in mediating lipid signaling in mammalian cells including the skeletal 
muscle cells (myocytes). Therefore, we hypothesized that statins would mediate skeletal muscle 
myocyte damage through activation of the PLD-mediated lipid signaling, and inhibition of PLD 
activation would protect against the statin-induced myotoxicity. In order to test our hypothesis, 
we used the well-established C2C12 mouse skeletal muscle myoblast cell line and studied the 
PLD activation and cytotoxicity in vitro induced by two different widely used statins (mevastatin 
and simvastatin) by the CVD patients. Our studies revealed that the statins caused dose-
dependent (10-100 µM) and time-dependent (4-24 h) activation of PLD (as determined by the 
[32]P-labeling of cells and thin-layer chromatography of phosphatidylbutanol formation) and 
cytotoxicity and mitochondrial dysfunction (as determined by the release of intracellular lactate 
dehydrogenase, suppression of MTT reduction, and alterations in cell morphology) in the C2C12 
myoblast cells. Our results also showed that cholesterol replenishment protected against the 
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statin-induced toxicity to the C2C12 cells. Furthermore, our results showed that the novel PLD-
specific inhibitor, 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) inhibited the statin-induced 
PLD activation and cytotoxicity in the C2C12 myoblast cells. For the first time, our current study 
demonstrated the role of endogenous cellular cholesterol depletion and PLD-mediated lipid 
signaling in the statin-induced skeletal muscle myocyte damage and emphasized the importance 
of PLD inhibition in attenuating the statin-induced myotoxicity and myalgia in CVD patients 
consuming statins to lower the elevated levels of endogenous cholesterol. 
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INTRODUCTION 
Cardiovascular Diseases 
 In developed countries across the world, and particularly in the United States, 
cardiovascular diseases (CVDs) including the cerebrovascular diseases claim the spot as the 
number one cause of death (Stock et al., 2012; Sowers et al., 2001). CVDs are the result of 
restricted blood vessels that lead to chest pain, stroke, or heart attack, and can also classify other 
heart conditions that cause an individual pain. Pathological conditions including rheumatic heart 
disease, the inflammation of the heart tissue; atherosclerosis, the clogging of arteries with fat and 
cholesterol; and vascular inflammation serve as some of the most common cardiovascular 
diseases that act as a detriment to health in the American population (Essop and Peters., 2014; 
Granger et al., 2004; Chen et al., 2012; Varghese, 2014; Xiong et al., 2012).  
CVDs have a variety of causes, both congenital and acquired. Congenital CVD means 
that an individual born with an abnormality of the cardiovascular system is either predisposed to 
or born with a cardiovascular disease (Nasr and Kussman, 2014; Singh et al., 2014). Various 
abnormalities of the heart chambers, septa, valves, arteries or veins, all present at birth, can serve 
as the cause of congenital cardiovascular disease. Acquired cardiovascular disease means that an 
individual’s lifestyle choices or environment have contributed to a condition affecting his or her 
cardiovascular system that did not present itself at birth. A diet high in fat and cholesterol, lack 
of exercise, use of tobacco, drugs, and alcohol, and a stressful environment serve as the primary 
risk factors for CVDs (Lamarche and Couture, 2014; Gielen et al., 2015; Buttar et al., 2005; 
Salabei and Conklin, 2013; Katsiki et al., 2014; Hartley et al., 2014). High concentrations of 
circulating blood cholesterol can cause the deposition of this cholesterol in blood vessels and 
eventually lead to plaque formation in the blood vessel and ultimate obstruction of the circulation 
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to vital organs including the heart, brain, and kidney (Badimon L and Vilahur, 2012; Cozma et 
al., 2009; Sander and Giles, 2002; Madden et al., 2012). Many individuals whose lifestyles put 
them at risk of developing CVDs have the opportunity to modify their diets, exercise routines, 
and lifestyle choices; however, it has become increasingly common for medical professionals to 
prescribe drugs that lower endogenously synthesized cholesterol in order to lower the risk for 
cardiovascular disease (Ewang-Emukowhate and Wierzbicki, 2013). 
Cholesterol and Cardiovascular Diseases 
Cholesterol is the major component of the cell membrane lipid backbone that regulates 
the membrane fluidity, structure, and function (Cortes et al., 2014; Owen and Gaus, 2013). Also, 
cholesterol occurs in circulation in two different types, including high-density lipoproteins 
(HDLs) and low-density lipoproteins (LDLs) (Najam and Ray, 2015; Scanu and Wisdom, 1972). 
The HDLs can reduce the risk for heart disease when in high concentrations, and thus often earn 
the name “good cholesterol” (Rached et al., 2015) The LDLs can clog vessels when in high 
concentrations, and thus often earn the name “bad cholesterol” (Elshourbagy et al., 2014). 
Having high concentrations of LDL-cholesterol (LDL-C) is referred to as hypercholesterolemia, 
and can have genetic or dietary roots (Elshourbagy et al., 2014).  
Familial hypercholesterolemia is an endogenous, inherited condition in which an 
individual has a deficiency of LDL-C receptors on the surfaces of human cells (Santos and 
Maranhao, 2014). These receptors would normally transport LDL-C into the cells, so a 
deficiency in receptors results in a high concentration of circulating LDL-C in the bloodstream 
that can accumulate on the vessel walls. In addition, feedback inhibition usually stops the 
synthesis of more cholesterol by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-
CoA reductase), a rate-limiting enzyme in cholesterol synthesis (Schema-1), when high 
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concentrations are detected in the blood, but individuals with familial hypercholesterolemia do 
not have this feedback inhibition, so their cells continue to synthesize cholesterol (Trapani et al., 
2011; McPherson, 2012; Salakhutdinov et al., 2011) (Schema-1). Dietary hypercholesterolemia 
results from a diet high in saturated fats and cholesterol, more than an individual can utilize. The 
excessive amount of cholesterol consumed finds its way into the blood stream and can 
accumulate on vessel walls leading to plaque formation and atherosclerotic lesions in the blood 
vessel that would obstruct blood flow leading to the CVDs and cerebrovascular disorders. 
Statins as the Endogenous Cholesterol-lowering Drugs 
Current therapeutic intervention for hypercholesterolemia involves the use of HMG-CoA 
reductase-specific inhibitors, known as statins (see the diagram of chemical structures of statins), 
to attenuate or suppress the synthesis of endogenous cholesterol (Trapani et al., 2011; 
McPherson, 2012; Salakhutdinov et al., 2011). By suppressing or inhibiting the endogenous 
cholesterol synthesis, there exists lowered levels of LDL-C in the blood circulation, and as a 
result the risk for blood vessel clogging or plaque formation decreases. Popular statins in the 
clinical use include atorvastatin (Lipitor), pravastatin (Pravachol), simvastatin (Zocor), 
mevastatin (Compactin), and lovastatin (Altoprev) (Malinowski, 1998; Moghadasian et al., 1998; 
Opie, 2015). 
One of the downsides to statin use is the myotoxicity associated with those cholesterol-
lowering drugs, called the “statin myalgia” or the “statin-induced myalgia” (Ganga et al., 2014). 
Studies have shown that statin use in certain individuals results in “statin intolerance” that is 
associated with myotoxicity, as a significant percentage of those administering statins experience 
painful side effects in their skeletal muscles and bones (Ahmad, 2014). Statins have pleiotropic 
effects once introduced into the body, but the mechanism through which they cause myalgia 
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remains unclear. If understood, the safety and effectiveness of statins could increase. It seems 
there exist multiple mechanisms through which statins cause myotoxicity, one being the 
mitochondrial mechanism, which holds valid to some extent (Sirvent et al., 2008). In this 
mechanism, statins cause damage to the mitochondria of the skeletal myocyte, which reduces the 
energy metabolism of the cell and can ultimately result in cell death (Dirks and Jones, 2006). 
Having this as the precedence, here it is hypothesized that statins cause membrane lipid signaling 
perturbation and mitochondrial dysfunction through cholesterol depletion, which ultimately leads 
to statin-induced myalgia. 
Lipid Signaling and Statin-induced Myotoxicity or Myalgia 
 The phospholipid bilayer forms a barrier between the cell and the external environment. 
Membrane phospholipids, protein channels, and cholesterol compose much of the membrane 
bilayer of living cells including that of human (Korn, 1969; Siekevitz, 1972; Suetsugu et al., 
2014). The bilayer must have the ability to interact with the environment, detect the external and 
internal environments of the cells, and relay information to the cell, wherein the membrane lipid 
signaling accomplishes these goals (Slone and Fleming, 2014). Phospholipases are the house-
keeping enzymes that can hydrolyze the membrane phospholipids during the turnover of the 
membrane phospholipids and also form different bioactive lipid molecules, each with an 
associated membrane lipid signal as interpreted by the cell. Four major phospholipases exist, 
including the phospholipase A1, A2, C, and D, and each catalyzes a specific hydrolysis of the 
membrane phospholipid within the cell (Richmond and Smith, 2011; Tani et al., 2012; Ghosh et 
al., 2006; Krizaj, 2014; Zhang and Frohman, 2014; Follo et al., 2015). Specifically, the 
phospholipase D (PLD) hydrolyzes the membrane phospholipid (phosphatidylcholine, PC) 
releasing the phosphatidic acid (PA) which can act as a potent bioactive cell signaling mediator 
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(Gomez-Cambronero, 2014; Zhang and Frohman, 2014). The cell can further convert the PLD-
generated PA to potent bioactive lipid signal mediators such as the lysophosphatidic acid (LPA) 
or diacylglycerol (DAG) upon the actions of phospholipase A1 (PLA1) or PLA2, which can 
cause myotoxicity (Schema-2) (Parinandi et al., 1999; Parinandi et al., 2001; Cummings et al., 
2002; Patel et al., 2011; Secor et al., 2011; Varadharaj et al., 2006). It has been demonstrated that 
lowering of cell membrane cholesterol in the vascular endothelial cells leads to the activation of 
PLD and generation of PA (Kline et al., 2010). Therefore, here it is hypothesized that statins 
cause cholesterol depletion in the membranes of the skeletal muscle cells through the inhibition 
of HMG-CoA reductase, leading to the activation of PLD that generates the bioactive lipid signal 
mediator (PA), which in turn results in the mitochondrial damage and myotoxicity as a 
mechanistic basis of the statin-induced myalgia or myotoxicity. In order to test our hypothesis, in 
the current study, we chose the well-established skeletal muscle cell model, the C2C12 myoblast 
cells. Our studies revealed that the two widely used statins (HMG-CoA reductase inhibitors), 
mevastatin and simvastatin, to lower the elevated levels of endogenous cholesterol in circulation 
as the therapeutic strategy to protect against the hypercholesterolemia-induced CVDs, caused 
PLD activation and generation of the bioactive lipid signal mediator (PA) leading to the 
mitochondrial dysfunction and cytotoxicity in the C2C12 myoblast cells through cholesterol 
depletion. 
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MATERIALS & METHODS 
Materials 
Mouse skeletal muscle myoblast cells (C2C12s) (passage 2) were obtained from Cell 
Applications Inc. (San Diego, CA). Phosphate-buffered saline (PBS) was purchased from 
Biofluids Inc (Rockville, Maryland). Minimal Essential Medium (MEM), FBS, trypsin, 
nonessential amino acids, penicillin/streptomycin, Dulbecco Modified Eagle Medium (DMEM) 
tissue culture reagents, phosphate-free modified medium, 3-[4,5-dimethylthiazol-2-yl]-2, 5-
diphenyl tetrazolium bromide reduction kit (MTT assay kit), lactate dehydrogenase cytotoxicity 
assay kit (LDH release assay kit), and analytical reagents of the highest purity were all obtained 
from Sigma Chemical Co (St Louis, Missouri). Phosphatidylbutanol (PBt), was acquired from 
Avanti Polar Lipids (Alabaster, Alabama). [32P]orthophosphate (carrier-free) was purchased 
from New England Nuclear (Wilmington, Delaware). Anti-rabbit AlexaFluor 488-conjugated 
antibody and the Amplex Red cholesterol determination kit were purchased from Molecular 
Probes Invitrogen Co (Carlsbad, California). 5-Fluoro-2-indolyl des-chlorohalopemide 
hydrochloride hydrate (FIPI) was prepared as described in earlier publications (Secor et al., 
2011; Patel et al., 2011).  All other reagents were acquired from the Sigma Chemical Company 
(St. Louis, MO).  
 
In Vitro Cell Culture 
The C2C12 myoblast cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and antibiotics up to 90-100% confluence in sterile 35-
mm or 60-mm dishes and in 96-well plates under a sterile and humidified atmosphere of 95% 
air-5% CO2 at 37o C. C2C12s were used up to passage 20 for experiments. 
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Assay of Phospholipase D (PLD) Activation 
  PLD activity in the C2C12 myoblast cells was determined according to our previously 
published procedure (Patel et. al., 2011: Secor et al., 2011). C2C12 myoblast cells cultured in 35-
mm dishes were labeled with [32P]orthophosphate (5 mCi/ml) in DMEM phosphate-free medium 
containing 2% (vol/vol) fetal bovine serum for 14 h. Following the experimental treatments for 
the chosen periods of time, [32P]-labeled phosphatidylbutanol ([32P]PBt) formed from the PLD 
activation and transphosphatidylation reaction in cellular lipid extracts, as an index of PLD 
activity in intact cells, was separated by thin-layer chromatography (TLC). Radioactivity 
associated with the [32P]PBt was quantified by liquid scintillation counting and data were 
expressed as DPM normalized to the total [32P] in the lipid extract of the cells in the dish. 
 
Lactate Dehydrogenase (LDH) Release Assay of Cytotoxicity  
The C2C12 myoblast cells were grown up to 90-100% confluence in sterile 15.5-mm 
dishes (24-well culture plate) and treated with DMEM alone or DMEM containing the chosen 
concentrations of statins and/or FIPI at designated time points.  At the end of the incubation 
period, the supernatant was removed, and the level of lactate dehydrogenase (LDH) activity was 
measured spectrophotometrically according to the manufacturer’s protocol (Sigma Chemical 
Co., St. Louis, MO).  
  
MTT Cell Proliferation Assay 
The C2C12 myoblast cells were grown up to 90-100% confluence in sterile 15.5-mm 
dishes (24-well culture plate) and treated with DMEM alone or DMEM containing the chosen 
concentrations of statins and/or FIPI at designated time points.  At the end of the incubation 
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period, the supernatant was removed, and the extent of MTT reduction was measured 
spectrophotometrically according to the manufacturer’s protocols (Cayman Chemical Co., Ann 
Arbor, MI).  
  
Cellular Morphology 
Morphological changes in the C2C12 myoblast cells grown in the sterile 35-mm dishes 
up to 90-100% confluence, following their exposure to the chosen concentrations of statins 
and/or FIPI for different time periods, were examined under light microscope as an index of 
cytotoxicity.  Images of cell morphology were digitally captured using the Zeiss Axioskop 200 
with Zen 2011 software at 20X magnification.  
 
Cholesterol Determination 
The C2C12 myoblast cells were grown up to 90-100% confluence in sterile 60-mm 
dishes, and treated with DMEM alone or DMEM containing the chosen concentrations of statins 
and/or FIPI for the chosen periods of time. Cells were then liberated from dish, reconstituted in 
PBS, and protein was determined following the protein determination by the BCA assay. 
Cholesterol contents in the samples was normalized to the total cellular protein (1 mg) according 
to our previously published method (Hinzey et. al., 2012). 
 
Phospholipase D1 (PLD1) Phosphorylation Visualization by Confocal Immunofluorescence 
Microscopy 
The C2C12 myoblast cells were grown on sterile glass cover slips (~90% confluence) 
and treated with DMEM alone or DMEM containing chosen concentrations of statins for 12 h. 
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Cover slips were then rinsed three times with PBS, and fixed with 3.7% formaldehyde in PBS for 
10 min. at room temperature. The cells were permeabilized in 0.25 % Triton X-100 prepared in 
PBS containing 0.01% Tween-20 (PBS-T) for 5 min. The cells were again washed three times 
with PBS-T, and treated with PBS-T containing 1 % BSA blocking buffer for 30 min. at room 
temperature. Cover slips were then incubated overnight at room temperature with the primary 
antibody [phospho-PLD1 (1:150 dilution)] in 1% BSA solution. After rinsing three times with 
PBS-T, the cells were labeled with secondary AlexaFluor 488 (1:100 dilution) in 1% BSA in 
PBS-T for 1 h. Finally, the cells were washed three times with PBS-T, mounted, and examined 
under Zeiss LSM 710 Confocal/Multiphoton Microscope powered by Argon-2 laser with 500-
550 BP filter. The images were captured digitally and the average fluorescent intensity of 
triplicate samples was determined using ImageJ.   
 
Preparation of Solutions Containing Pharmacological Agents for Treatment of Cells  
All water-soluble pharmacological agent solutions were freshly formulated in DMEM for 
treatment of cells.  The stock solutions of lipophilic pharmacological agents including all statins 
and FIPI were freshly assembled in DMSO and then diluted in DMEM for treatment of cells. 
The final DMSO concentration in the cell treatment medium did not exceed 0.1% (vol/vol) and 
did not appear to have any influence on experimental outcomes.  
 
Statistical Analysis 
All experiments were completed in triplicate. Results were reported as mean ± standard 
deviation (SD). Statistical analysis of data was accomplished by one-way analysis of variance 
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(ANOVA) by use of the SigmaStat (Jandel Scientific, San Rafael, California). The statistical 
significance level was taken as p ≤ 0.05. 
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RESULTS 
Statins induce PLD activation in C2C12 myoblast cells. Statins, being the HMG-CoA 
reductase inhibitors are established to lower endogenous levels of cholesterol by inhibiting 
cellular cholesterol synthesis (Okayama et al., 2015; Bockorny and Dasanu, 2015). Also, in our 
earlier study, we have shown that the cholesterol-depleting agent such as the methyl-β-
cyclodextrin (MβCD) lowers cholesterol levels and causes activation of PLD in the vascular 
endothelial cells (Kline et al., 2010; Hinzey et al., 2012). Taking these as the premise, here we 
hypothesized that statin-induced decrease of cellular cholesterol would lead to activation of PLD 
in the myocyte model, the C2C12 myoblast cells. In order to test our hypothesis, in the current 
study, we treated the C2C12 cells with two selected statins, mevastatin and simvastatin for 
different periods of time (4-24 h) and assayed the activation of PLD. Here, we determined the 
activity of PLD by analyzing the intracellular formation of phosphatidylbutanol as the 
transphosphatidylation reaction product of PLD, which is an established and widely used assay 
of cellular PLD activity (Natarajan et al., 2001). Both chosen statins in the current study, 
mevastatin and simvastatin (10 µM) caused significant time-dependent activation of PLD in the 
C2C12 myoblast cells (Figs. 1A & 1B). Although the PLD activity peaked at 12 h under 
mevastatin treatment of cells, simvastatin caused a significant linear increase of the PLD activity 
from 4 h up to 24 h of treatment in a time-dependent manner as compared to the untreated 
control cells (Figs. 1A & 1B). At 12 h, mevastatin caused a 4.5-fold increase of PLD activation 
in the C2C12 cells as compared to the control untreated and mevastatin-treated cells at 4 h. 
However, the extent of PLD activity at 24 h although significantly increased in the mevastatin-
treated cells, it dropped markedly from that at 12 h of treatment in the C2C12 myoblast cells. On 
the other hand, simvastatin caused a significant and ~7-fold increase in PLD activity at 24 h as 
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compared to the same in the control untreated and simvastatin-treated cells at 4 h (Fig. 1B). One 
noteworthy response of the control untreated cells was that the basal PLD activity (formation of 
PA without statin treatment) also linearly increased with time (Figs. 1A & 1B). These results 
revealed that both mevastatin and simvastatin caused a significant activation of PLD in the 
C2C12 myoblast cells and simvastatin apparently was more potent than mevastatin in inducing 
the activation of PLD and generating the bioactive lipid signal mediator (PA) in cells. 
 
FIPI, the PLD-specific inhibitor attenuates statin-induced PLD activation in C2C12 cells. 
FIPI is the only available PLD-specific pharmacological inhibitor and in our earlier studies we 
used it in our cell culture models and reported its efficacy in causing inhibition of PLD activity 
(Secor et al., 2011; Patel et al., 2011). Here, in this study we used FIPI (i) to investigate its 
inhibitory action on the statin-induced PLD activation and (ii) to confirm that statins indeed 
activate PLD in the C2C12 myoblast cells. By virtue of its PLD-specific inhibitory action, FIPI 
(0.1-1 µM, 12 h of pretreatment) significantly and drastically inhibited the basal PLD activity in 
the control untreated C2C12 myoblast cells at 24 h (Figs. 2A & 2B). At 1 µM concentration, 
FIPI caused ~85-92% decrease of basal PLD activation in the control untreated cells (Figs. 2A & 
2B). Furthermore, FIPI, in a dose-dependent manner (0.1-1 µM), significantly and robustly 
attenuated the statin-induced PLD activation in cells treated with both mevastatin (10 µM) and 
simvastatin (10 µM) for 24 h as compared with the cells treated with statins alone (Figs. 2A & 
2B). FIPI (1 µM) significantly attenuated the statin-induced PLD activation by ~90-95% in cells 
treated with both mevastatin (10 µM) and simvastatin (10 µM) for 24 h as compared to the same 
in the C2C12 myoblast cells treated with statins alone (Figs. 2A & 2B). These results clearly 
revealed that (i) FIPI was a potent inhibitor of the statin-induced PLD activation at doses ranging 
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between 0.1-1 µM and the 1 µM dose was the most efficacious in causing effective inhibition of 
the statin-induced PLD activation and (ii) indeed, statins induced the activation of PLD in the 
C2C12 myoblast cells. 
 
Statins induce cytotoxicity in C2C12 cells. It is becoming increasing evident that the lipid-
lowering and cholesterol-depleting drugs such as the lipophilic statins cause cytotoxicity to the 
mammalian cells including the normal and malignant cells (Costa et al., 2013; Abdoli et al., 
2013; Kotamraju et al., 2007; Kanugula et al., 2014). Also, our earlier studies have revealed that 
the cyclodextrin-induced cellular cholesterol depletion causes cytotoxicity in the vascular 
endothelial cells in culture (Kline et al., 2010; Hinzey et al., 2012). Having these reports as the 
basis, here we investigated whether statins (simvastatin and mevastatin) would cause cytotoxicity 
in the C2C12 cells as determined by the lactate dehydrogenase (LDH) release from the cells. Our 
results revealed that both simvastatin and mevastatin (10-100 µM) significantly induced LDH 
release from the cells in a dose-dependent fashion at 24 h of exposure as compared to the same in 
the control untreated cells (Figs. 3A & 3B). Both statins at 10 µM dose caused robust and 
significant increase in the LDH release from cells (2-fold increase by simvastatin; 3.7-fold 
increase by mevastatin) and further increase in release of the intracellular LDH was not markedly 
enhanced by increasing the dose of statins at 24 h of treatment of the C2C12 cells (Figs. 3A & 
3B). Therefore, our current results revealed that statins (simvastatin and mevastatin) induced 
cytotoxicity in the C2C12 cells even at 10 µM dose as demonstrated by the release of 
intracellular LDH, the standard mammalian cytotoxicity assay. Furthermore, the results showed 
that mevastatin was more potent than simvastatin at 10 µM dose in causing cytotoxicity in the 
C2C12 myoblast cells (Figs. 3A & 3B).  
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Statins induce decrease of cholesterol in C2C12 cells. As statins are established to lower or 
decrease the cellular levels of cholesterol (Kotamraju et al., 2007), here we investigated whether 
statins would decrease/lower the cholesterol levels in the C2C12 myoblast cells. All the three 
tested statins (simvastatin, mevastatin, and lovastatin) at 10 µM dose caused significant decrease 
of intracellular cholesterol (25%, 21%, and 46% respectively) as compared to that in the control 
untreated cells at 24 h of treatment (Fig. 4A). Among all the chosen statins, lovastatin was the 
most effective statin in decreasing the intracellular cholesterol levels in the C2C12 myoblast 
cells. Therefore, these results revealed that statins caused significant decrease of the intracellular 
levels of cholesterol in the C2C12 myoblast cells. 
 
Cholesterol replenishment protects against statin-induced cytotoxicity in C2C12 cells. Our 
earlier studies have demonstrated that cholesterol replenishment offered protection against the 
cyclodextrin-induced cytotoxicity mediated through the intracellular cholesterol depletion in the 
vascular endothelial cells (Hinzey et al., 2012). In the current study, we showed that statins cause 
both cytotoxicity (LDH release) and cholesterol depletion. Therefore, here we investigated 
whether cholesterol replenishment would offer protection against the statin-induced cytotoxicity 
(LDH release) in the C2C12 myoblast cells. Our results revealed that both mevastatin (10 µM) 
and simvastatin (10 µM) caused significant cytotoxicity as revealed by the intracellular LDH 
release assay at 24 h of treatment with statins as compared to the control untreated cells (Figs. 4B 
& 4C). Furthermore, treatment of cells with the water-soluble (methylcyclodextrin-conjugated) 
cholesterol (1%) offered significant protection of the statin-induced cytotoxicity (attenuation of 
release of intracellular LDH) (Figs. 4B & 4C). However, cholesterol at 2% dose was not 
effective in lowering the mevastatin-induced release of intracellular LDH and failed to protect 
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against the mevastatin-induced cytotoxicity in the C2C12 cells as opposed to the protective 
action offered by cholesterol at 1% dose (Fig. 4B). On the other hand, cholesterol at 2% dose, 
although effective in significantly protecting against the simvastatin-induced cytotoxicity in the 
C2C12 cells, its protective action was less effective than that was offered by cholesterol at 1% 
dose (Fig. 4C). Overall, these results revealed that (i) cholesterol replenishment offered 
protection against the statin-induced cytotoxicity in the C2C12 cells as revealed by the 
intracellular LDH assay and (ii) lower dose of cholesterol (1%) was more effective in 
significantly protecting against the statin-induced cytotoxicity. 
 
FIPI, the PLD-specific inhibitor attenuates statin-induced cytotoxicity in C2C12 cells. We 
have earlier reported that the PLD-specific pharmacological inhibitor, FIPI protected against the 
oxidant- and drug-induced cytotoxicity mediated by the PLD-depended bioactive lipid signaling 
in the vascular endothelial cells (Patel et al., 2011; Secor et al., 2011). Therefore, here we 
investigated to show whether FIPI would offer protection against the statin-induced cytotoxicity 
(intracellular LDH release) in the C2C12 myoblast cells to demonstrate the role of PLD therein, 
since in the current study it was revealed that statins caused significant activation of PLD which 
was significantly attenuated by FIPI in the C2C12 myoblast cells (Figs. 1 & 2). Here, our current 
results revealed that FIPI (1 µM, pretreatment for 12 h) offered significant protection against 
simvastatin (10 µM)- and mevastatin (10 µM)-induced cytotoxicity at 24 h as demonstrated by 
the release of intracellular LDH (Fig. 5). Overall, the current study demonstrated that (i) the 
PLD-specific pharmacological inhibitor, FIPI offered significant protection of the statin-induced 
cytotoxicity and (ii) the PLD-mediated bioactive lipid signaling also was involved in the statin-
induced cytotoxicity in the C2C12 myoblast cells. 
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Statins induce mitochondrial dysfunction in C2C12 cells. It is rapidly emerging that statins 
cause mitochondrial dysfunction and damage in different organs/cells including the skeletal 
muscle, especially during the statin-induced myopathy (Stroes et al., 2015; Abdoli et al., 2014). 
Although MTT reduction by the mitochondria is used as a valid indicator of cell proliferation 
and cytotoxicity, the assay is also utilized to ascertain the mitochondrial function (Sliman et al., 
2010). Therefore, here we utilized the MTT reduction by the cellular mitochondria in the C2C12 
cells to demonstrate the statin-induced mitochondrial dysfunction since MTT is reduced by a 
mitochondria-specific dehydrogenase (Sliman et al., 2010). Both statins, simvastatin and 
mevastatin, in a dose-dependent fashion (10-100 µM) caused significant decrease of MTT 
reduction in the C2C12 cells at 24 h of treatment as compared to the control untreated cells (Figs. 
6A & 6B). Simvastatin (10 mM) and mevastatin (10 mM) significantly caused 51% and 60% 
decrease of MTT reduction, respectively by the C2C12 myoblast cells treated for 24 h as 
compared to the same in the control untreated cells (Figs. 6A & 6B). Therefore, these studies 
demonstrated that both mevastatin and simvastatin induced the mitochondrial dysfunction as 
revealed by the decrease in the MTT reduction by the C2C12 cells. 
 
FIPI, the PLD-specific inhibitor attenuates statin-induced mitochondrial dysfunction by 
C2C12 cells. In the earlier experiments of the current study, we had shown that (i) statins 
induced PLD activation, (ii) FIPI, the PLD-specific pharmacological inhibitor attenuated the 
statin-induced PLD activation, and (iii) FIPI offered protection against the statin-induced 
cytotoxicity (intracellular LDH release) in the C2C12 myoblasts.  Hence, here we investigated 
whether FIPI would attenuate the statin-induced mitochondrial dysfunction as assayed by the 
decrease of MTT reduction by the C2C12 cells to establish a link between the statin-induced 
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PLD activation and bioactive lipid signal mediator (PA) generation and mitochondrial 
dysfunction. FIPI (1 µM, 12 h of pretreatment) significantly and markedly attenuated the 
simvastatin (10 µM)- and mevastatin (10 µM)-induced decrease of MTT reduction by the C2C12 
cells (Fig. 7A). Furthermore, the results showed that the protective action of FIPI against the 
simvastatin-induced decrease of MTT reduction by the C2C12 cells was more pronounced than 
that induced by the mevastatin (Fig. 7A). Overall, these studies demonstrated that FIPI 
significantly attenuated the statin-induced mitochondrial dysfunction in the C2C12 myoblast 
cells as demonstrated by the mitochondria-specific MTT reduction assay, suggesting the role of 
PLD-generated bioactive lipid signal mediators therein.  
 
FIPI, the PLD-specific inhibitor attenuates statin-induced morphological alterations in 
C2C12 Cells. Our studies conducted so far in the current project revealed that statins (mevastatin 
and simvastatin) induced cytotoxicity and mitochondrial dysfunction that was mediated by the 
PLD-generated bioactive lipid signaling and cholesterol depletion in the C2C12 myoblast cells. 
Cell morphology alterations serve as an index of cytotoxicity induced by toxic stresses (Sliman 
et al., 2010; Patel et al., 2012). Here, we furthered to demonstrate that statins would induce the 
morphological alterations in the C2C12 myoblast cells, which might be protected by the PLD-
specific pharmacological inhibitor, FIPI. Simvastatin, mevastatin, and lovastatin at 10 µM dose 
caused severe cell morphological alteration at 24 h of treatment characterized by the light 
microscopic examinations including elongated myoblast cells turning into round and circular 
cells (Fig. 7B). This indicated the drastic changes in the morphological nature of the cells upon 
the statin treatment. However, FIPI pre-treatment (1 mM for 12 h) offered almost complete 
protection of the statin-induced morphological alterations in the C2C12 myoblast cells (Fig. 7B). 
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These results further confirmed that the statin-induced cell morphological alterations 
(cytotoxicity) was (i) protected by the PLD-specific pharmacological inhibitor, FIPI and (ii) 
PLD-generated bioactive lipid signaling through PA formation played a role in the statin-induced 
cell morphology alterations in the C2C12 cells. 
 
Statins induce threonine phosphorylation of PLD1 in C2C12 cells. Our earlier reports 
revealed that oxidant stress and heavy metal toxicity cause the protein kinase-mediated serine-
threonine phosphorylation of PLD isoenzymes upstream of PLD activation (Natarajan et al., 
2001; Secor et al., 2011). Since the protein kinase-mediated serine-threonine phosphorylation 
regulates the activity of PLD isoenzymes, in this study we investigated whether statins would 
induce threonine phosphorylation of PLD1 isoenzyme in the C2C12 myoblast cells as examined 
by the confocal immunofluorescence microscopy with the aid of PLD-phosphothreonine-specific 
antibody immunostaining. Both mevastatin and simvastatin at 10 µM dose induced intense 
phosphorylation of PLD1 isoenzyme in intact C2C12 myoblast cells at 12 h of treatment of cells 
with the statins (upstream of maximal PLD activation at 24 h) as compared to the same in the 
control untreated cells (Fig. 8). This study demonstrated that statins induce serine 
phosphorylation of PLD1 isoenzyme upstream of the activation of the enzyme. 
 
 
 
 
 
 
25	  
	  
DISCUSSION 
 High cholesterol levels (hypercholesterolemia) in circulation of humans have been 
considered as a risk factor for the vascular disorders, cardiovascular diseases (CVDs), 
cerebrovascular diseases, and chronic heart diseases (CHD). Therefore, aggress therapy with the 
cholesterol-lowering drugs to lower the endogenously synthesized cholesterol have been in 
practice currently (Trapani et al., 2011; McPherson, 2012; Salakhutdinov et al., 2011; 
Malinowski, 1998; Moghadasian et al., 1998; Opie, 2015). The cholesterol-lowering drugs to 
combat the elevated levels of endogenously synthesized cholesterol are the statins, which are the 
HMG-CoA reductase-specific inhibitors since the HMG-CoA reductase is a rate-limiting enzyme 
in the cholesterol biosynthetic pathway (Schema-1) (Trapani et al., 2011; McPherson, 2012; 
Salakhutdinov et al., 2011). However, it is increasingly becoming evident that statins used for 
cholesterol-lowering cause adverse effects such as statin myalgia or statin myotoxicity (Ganga et 
al., 2014; Ahmad, 2014). Although a few mechanisms have been put forth to pinpoint the exact 
nature of the statin-induced myotoxicity or myalgia among patients with hypercholesterolemia 
and CVDs which include mitochondrial dysfunction, apoptotic pathway, and coenzyme-Q10 
(CoQ10) depetion (Sirvent et al., 2008; Dirks and Jones, 2006; Stroes et al., 2015; Kotamraju et 
al., 2007). Nevertheless, there is still a void in understanding the exact mechanism of statin-
induced myotoxicity or myalgia. Therefore, here in the current study we hypothesized that statins 
would cause cholesterol depletion in the membranes of the skeletal muscle cells through the 
inhibition of HMG-CoA reductase (Schema-1), leading to the activation of PLD that could 
generate the bioactive lipid signal mediator (PA) (Schema-2), which in turn might result in the 
mitochondrial damage and myotoxicity as a mechanistic basis of the statin-induced myalgia or 
myotoxicity. To test our hypothesis, we utilized the well-established skeletal muscle cell model, 
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the C2C12 myoblast cells. The current study demonstrated that the two widely used statins 
(HMG-CoA reductase inhibitors), mevastatin and simvastatin to lower the elevated circulating 
levels of endogenous cholesterol to combat the hypercholesterolemia-induced CVDs, induced 
the PLD activation and formation of the bioactive lipid signal mediator (PA) causing the 
mitochondrial dysfunction and cytotoxicity in the skeletal muscle cell model (C2C12 myoblast 
cells) through the decrease of endogenous cholesterol (Schema-3). 
 By virtue of their ability to selectively inhibit the rate-limiting enzyme in the cholesterol 
biosynthetic pathway in the mammalian cells, the potent HMG-CoA reductase inhibitors, statins 
drastically decrease or deplete the endogenous levels of cholesterol. On the other hand, 
cholesterol is an important lipidic component of the cell membranes that regulates the membrane 
structure and function (Cortes et al., 2014; Owen and Gaus, 2013). If the cholesterol levels and 
packing in the cell membranes are altered, the cell would face dire consequences such as 
cytotoxicity and cell death. Our earlier studies have demonstrated that the widely used 
experimental cholesterol-depleting agent, methyl-β-cyclodextrin (MβCD) causes cytotoxicity to 
the vascular endothelial cells through the cellular cholesterol depletion and cholesterol 
replenishment following the MβCD-mediated cholesterol depletion of the cells restores the cell 
viability, suggesting that the cellular cholesterol plays a crucial role in maintaining the viability 
of the mammalian cells (Kline et al., 2010; Hinzey et al., 2012). Along these lines, it could be 
surmised that the statin-induced cytotoxicity in the C2C12 myoblast cells as observed in the 
current study was caused by the statin-mediated depletion of cellular cholesterol in the skeletal 
muscle cell model. This was also confirmed by replenishing the cells with the water-soluble 
cholesterol which rescued the cells from statin-induced cytotoxicity. Therefore, it could be 
unequivocally stated that the statin-mediated cellular cholesterol depletion could be among the 
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prime causes of the statin-induced myotoxicity operating behind the statin-induced myotoxicity 
or myalgia.   
 Phospholipase D (PLD) is ubiquitously present in mammalian cells which belongs to the 
family of phospholipases that conduct the membrane phospholipid hydrolysis (Schema-2) 
(Parinandi et al., 1999 & 2001; Secor et al., 2011; Patel et al., 2011; Cummings et al., 2002; 
Varadharaj et al., 2006). Although PLD is a house-keeping enzyme involved in the metabolism 
of membrane phospholipids, the enzyme is known to be activated by a variety of agonists 
including hormones, reactive oxygen species, heavy metals, toxins, and metabolic stresses 
(Parinandi et al., 1999 & 2001; Secor et al., 2011; Patel et al., 2011; Cummings et al., 2002; 
Varadharaj et al., 2006). PLD exists in the cells as two isoforms such as PLD1 and PLD2 
(Parinandi et al., 1999 & 2001; Secor et al., 2011; Patel et al., 2011; Cummings et al., 2002; 
Varadharaj et al., 2006) which are localized in different cellular compartments such as the 
cytosol and nucleus. These isoforms can be translocated and activated by the agonists. Protein 
kinases such as mitogen-activated protein kinases (MAPKs), protein tyrosine kinases, protein 
kinase C, G-protein coupled receptors, and receptor-mediated kinases phosphorylate the PLD 
isoforms at the corresponding amino acid residues (serine or threonine or tyrosine), cause the 
translocation of these isoforms and activate them (Parinandi et al., 1999 & 2001; Secor et al., 
2011; Patel et al., 2011; Cummings et al., 2002; Varadharaj et al., 2006). Thus the PLD isoforms 
in the cells upon activation by the agonists hydrolyze the cell membrane phospholipids (e.g. 
phosphatidylcholine) and form the most potent bioactive signal lipid, the PA (Secor et al., 2011; 
Patel et al., 2011). PA is known to be capable of causing cytotoxicity and cellular cytoskeletal 
alterations that could lead to the dysfunction of the cells and even cell death (Secor et al., 2011; 
Patel et al., 2011). The PLD-generated PA can further be transformed by either PLA1 or PLA2 
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into LPA or by lipid phosphate phosphohydrolase into DAG (Parinandi et al., 1999 & 2001; 
Secor et al., 2011; Patel et al., 2011; Cummings et al., 2002; Varadharaj et al., 2006). Both LPA 
and DAG are potent bioactive signal mediators which are involved in invoking the adverse 
cellular responses. Our earlier studies have demonstrated that the cholesterol depletion mediated 
by MβCD in the vascular endothelial cells leads to the activation of PLD causing cytotoxicity 
through the generation of the lipid signal mediator, PA (Kline et al., 2010). Along these lines, in 
the current study it was demonstrated for the first time that statins induced the activation of PLD 
in the C2C12 cells which was attenuated by the PLD-specific inhibitor, FIPI. Furthermore, the 
current study also showed that the PLD-specific inhibitor, FIPI effectively protected against the 
statin-induced cytotoxicity. The results of the current study also revealed that statins induced the 
upstream threonine phosphorylation of PLD1 isoenzyme in the C2C12 cells that could have been 
mediated by the MAPKs or PKC leading to the translocation and activation of the enzyme as 
previously observed in other cellular models. Thus, a connection between statin-induced PLD 
activation and statin cytotoxicity in the C2C12 muscle cell model offers a PLD-dependent 
mechanism of statin myotoxicity and myalgia suggesting a role of the PLD-generated bioactive 
lipids such as PA, LPA, and DAG therein.  
 In the current study, it was shown that statins caused the mitochondrial dysfunction as 
determined by the MTT reduction ability in the C2C12 cells (Sliman et al., 2010). The statin-
induced mitochondrial dysfunction (decrease in MTT reduction catalyzed by the mitochondrial 
dehydrogenase) and cytotoxic cell morphology alterations were attenuated by the PLD-specific 
inhibitor. This suggested a reasonable connection or association with the PLD activation and 
subsequent generation of the bioactive signal lipid mediators (PA, LPA, and DAG) and the 
mitochondrial dysfunction and cytotoxicity in the C2C12 myoblast cells. However, other 
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mitochondria-driven mechanisms of the statin-induced myotoxicity such as apoptosis, CoQ10 
loss, decline of ATP production, and reactive oxygen species generation are not ruled out in 
mediating the statin-induced cytotoxicity in the C2C12 cells. 
 Overall the current study demonstrated that the cholesterol-lowering HMG-CoA inhibitor 
drugs, statins, caused the cellular cholesterol depletion leading to the activation of PLD which in 
turn caused the mitochondrial dysfunction and cytotoxicity in the skeletal muscle cell model, 
C2C12 cells (Schema-3). Thus, it is highly reasonable to ascertain that PLD activation and 
formation of the PLD-generated bioactive lipids could act as potential players in the statin-
induce myalgia and myotoxicity. Therefore, PLD could be a pharmacological target for 
combating the statin myotoxicity. 
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LIST OF ABBREVIATIONS 
ATP: adenosine 5-phosphate 
BCA: bicinchoninic acid  
BSA: bovine serum albumin 
CoQ10: coenzyme Q10 
CVD: cardiovascular disease 
CHD: chronic heart disease 
DAG: diacylglycerol 
DMEM: Dulbecco’s modified Eagle medium 
DMSO: dimethylsulfoxide 
EDTA: ethylenediaminetetraacetic acid 
FBS: fetal bovine serum 
FIPI: 5-fluoro-2-indolyl des-chlorohalopemide hydrochloride hydrate 
HDL: high-density lipoprotein 
HMG-CoA reductase: 3-hydroxy-3-methyl-glutaryl-CoA reductase 
LDH: lactate dehydrogenase 
LDL-C: low-density lipoprotein-cholesterol 
LPA: lysophosphatidic acid 
MAPK: mitogen-activated protein kinase 
MβCD: methyl-β-cyclodextrin 
MEM: minimal essential medium 
MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
PA: phosphatidic acid 
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PBS: phosphate-buffered saline 
PBS-T: phosphate-buffered saline-Tween-20 
PBt: phosphatidylbutanol 
PKC: protein kinase C 
PLA2: phospholipase A2 
PLD: phospholipase D 
ROS: reactive oxygen species 
TLC: thin-layer chromatography 
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